Genedx Holdings Corp. ( (WGS) ) has released its Q3 earnings. Here is a breakdown of the information Genedx Holdings Corp. presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
GeneDx Holdings Corp., a leader in genomic insights, focuses on improving health outcomes through advanced genomic testing, particularly in rare disease diagnosis. In its third quarter of 2025, GeneDx reported significant financial growth, with revenues reaching $116.7 million, marking a 52% increase year-over-year. The company also achieved a 65% rise in exome and genome test revenue and expanded its adjusted gross margin to 74%. Notably, GeneDx received FDA Breakthrough Device Designation for its ExomeDx™ and GenomeDx™ tests, highlighting its innovative edge in genomic medicine. Key financial metrics include an adjusted net income of $14.7 million and a robust cash position of $156.1 million. The company also raised its full-year revenue guidance to between $425 and $428 million, reflecting anticipated growth in exome and genome testing. Looking ahead, GeneDx aims to capitalize on its market leadership and continue its expansion in genomic newborn screening and precision medicine, setting the stage for sustained growth and innovation.